Free Trial
Your $100 Credit Is Waiting! Get MarketBeat All Access Today
Lock In $149
Claim MarketBeat All Access Sale Promotion
NASDAQ:JUNS

Jupiter Neurosciences 8/18/2025 Earnings Report

Jupiter Neurosciences logo
$0.32 -0.01 (-3.70%)
Closing price 03:59 PM Eastern
Extended Trading
$0.32 +0.01 (+1.56%)
As of 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Jupiter Neurosciences EPS Results

Actual EPS
-$0.07
Consensus EPS
-$0.07
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Jupiter Neurosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Jupiter Neurosciences Announcement Details

Quarter
Date
8/18/2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Jupiter Neurosciences' next earnings date is estimated for Thursday, May 21, 2026, based on past reporting schedules.

Conference Call Resources

Jupiter Neurosciences Earnings Headlines

Jupiter Neurosciences (JUNS) Projected to Post Earnings on Thursday
May 14, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30776696
Analyzing Jupiter Neurosciences (JUNS) & The Competition
May 11, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30772210
The Iran War Just Broke the Gold Market
The Iran war isn't just a geopolitical event. It's a financial one. Within hours of the strikes, oil surged… Defense stocks exploded…And gold ripped past $5,000.tc pixel
May 19 at 1:00 AM  |  Behind the Markets (Ad)
Jupiter Neurosciences: Resveratrol for neuroinflammation & CNS diseases
May 9, 2026  |  msn.comhttps://www.msn.com/en-us/health/medical/jupiter-neurosciences-resveratrol-for-neuroinflammation-cns-diseases/vi-AA22KRHt
Jupiter Neurosciences Investor News: Rosen Law Firm Encourages Jupiter Neurosciences, Inc. Investors to Inquire About Securities Class Action Investigation – JUNS
April 13, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260413104636/en/jupiter-neurosciences-investor-news-rosen-law-firm-encourages-jupiter-neurosciences-inc.-investors-to-inquire-about-securities-class-action-investigation-%e2%80%93-juns/
Rosen Law Firm Encourages Jupiter Neurosciences, Inc. Investors to Inquire About Securities Class Action Investigation - JUNS
April 13, 2026  |  tmcnet.comhttps://www.tmcnet.com/usubmit/2026/04/12/10363002.htm
See More Jupiter Neurosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Jupiter Neurosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Jupiter Neurosciences and other key companies, straight to your email.

About Jupiter Neurosciences

Jupiter Neurosciences (NASDAQ:JUNS), a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.

View Jupiter Neurosciences Profile
Earnings Tools